View PDF Version - RePub - Erasmus Universiteit Rotterdam

log HBV DNA (copies/mL)
10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
0
5
10 15
Time (days)
20
Patient J
R-R
25
30
Viral dynamics during tenofovir therapy 199
10 15
Time (days)
20
Figure 1. Viral decline during the first 4 weeks of tenofovir therapy in 11 lamivudine-resistant patients.
Each individual patient could be fitted using the biphasic model. The vertical straight dotted line
represents the time of transition from the first-to the second-phase for each individual patient. When
describing the different patterns of viral decay, the first week represents the first-phase; the secondphase
begins at day 8. In this study, the first-phase was categorized to one of the three patterns
according to the rate of hepatitis B virus (HBV)-DNA decline in the first 7 days: rapid (R) with a decline
of =1 log, slow (S) for a decline between 0.5 and 1 log, or flat (F) for a decline of 1 log HBV-DNA over the 4-week period, S for slow declines of
between 0.2 and 1 log HBV-DNA over 4 weeks, F for flat declines of